---
schema_version: "secwatch.filing_event.v1"
accession: "0001672688-25-000082"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:18:37.092528+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Absci Reports Q3 2025 Results, Advances ABS-201 and ABS-101 Programs

## Summary
- Reported interim Phase 1 data for ABS-101 (anti-TL1A) showing extended half-life with no serious adverse events.
- Accelerated initiation of Phase 1/2a trial for ABS-201 in androgenetic alopecia to December 2025.
- Expanding ABS-201 strategy to endometriosis, targeting Phase 2 start in Q4 2026 and proof-of-concept in H2 2027.
- Cash, cash equivalents, and marketable securities totaled $152.5 million as of Sept 30, 2025, funding operations into H1 2028.
- Net loss was $28.7 million for Q3 2025, compared to $27.4 million in Q3 2024.

## SEC filing metadata
- accession: 0001672688-25-000082
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/0001672688-25-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/absc-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001672688-25-000082
- JSON: https://secwatch.observer/filing/0001672688-25-000082.json
- Plain text: https://secwatch.observer/filing/0001672688-25-000082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.